AmadeusValue’s Newsletter

AmadeusValue’s Newsletter

Home
Archive
About
Part 2 / 2: Portfolio going into 2025
$BFF.IM, $SES.IM, $8291.JP, $CCG.AX - and more to come...
Jan 3 • 
AmadeusValue
21

Share this post

AmadeusValue’s Newsletter
AmadeusValue’s Newsletter
Part 2 / 2: Portfolio going into 2025
4
Part 1 / 2: Update and context, approach going forward
Portfolio going into 2025 revealed in my next post
Jan 2 • 
AmadeusValue
14

Share this post

AmadeusValue’s Newsletter
AmadeusValue’s Newsletter
Part 1 / 2: Update and context, approach going forward
Aclaris Therapeutics ($ACRS)
An intriguing busted biotech situation ($1.15 share price, $81.53m market cap, >$1.5m USD ADTV). Upside estimate of +27-58%, or assuming a six-month…
Feb 6, 2024 • 
AmadeusValue
6

Share this post

AmadeusValue’s Newsletter
AmadeusValue’s Newsletter
Aclaris Therapeutics ($ACRS)
16
Comms Group (CCG AX)
An Australian nano-cap lollapalooza offering +170% to +250% returns over the next three years
Feb 25, 2022 • 
AmadeusValue
10

Share this post

AmadeusValue’s Newsletter
AmadeusValue’s Newsletter
Comms Group (CCG AX)
7
My background, objectives and investment process
Inaugural post
Jun 11, 2021 • 
AmadeusValue
9

Share this post

AmadeusValue’s Newsletter
AmadeusValue’s Newsletter
My background, objectives and investment process
3
Global opportunistic value investing in inefficient markets
Welcome to AmadeusValue’s Newsletter by me, AmadeusValue.
Jun 10, 2021 • 
AmadeusValue
2

Share this post

AmadeusValue’s Newsletter
AmadeusValue’s Newsletter
Global opportunistic value investing in inefficient markets
AmadeusValue’s Newsletter
AmadeusValue’s Newsletter
Global opportunistic value investing in inefficient markets

AmadeusValue’s Newsletter

AboutArchiveSitemap

Share this publication

AmadeusValue’s Newsletter
amadeusvalue
AmadeusValue’s Newsletter
© 2025 AmadeusValue
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share